Nursing · Independent exam preparation
CARN-AP: Clinical Decisions and Practice Guide Study Guide
Practise withdrawal triage, medication selection, overdose response, and coordinated addiction care through 60 focused concepts and 20 original CARN-AP questions.
By CertMedbry · Updated 27 October 2026
Practise deciding who needs urgent stabilization, which addiction medications fit a patient's risks, how to interpret drug tests, and how to coordinate continuing care. This selective guide develops 60 clinical and professional concepts across the 2026 CARN-AP activity domains. The official test specifications define the full examination scope, including patient-problem categories that extend beyond these examples. The questions and flashcards support learning and do not predict examination performance.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and jurisdictional context does this guide address?
The pathway is ANCB's Certified Addictions Registered Nurse-Advanced Practice, or CARN-AP. ANCB distinguishes it from CARN and states that it certifies nurses in the United States and Canada. Eligibility, professional licensure, and prescribing authority remain separate matters. The advanced practice eligibility requirements should be checked through C-NET for the applicant's circumstances.
ANCB — Home · Certified Addictions Registered Nurse Advanced Practice — C-NET
How many questions are included, and how many are scored?
The handbook revised January 2026 describes 150 questions, with approximately 25 unscored pilot questions. This implies approximately 125 scored questions; the pilot count is approximate, so an exact scored count should not be inferred. Candidates should give every question their best response.
What testing time and delivery method are verified?
The January 2026 handbook allows four hours of testing. C-NET lists year-round computer-based testing, with eligible candidates scheduling an examination date, time, and location. The examination uses multiple-choice questions with a single best answer. The four-option questions in this guide are independent learning drills.
CARN-AP Examination Handbook — Revised January 2026 · Certified Addictions Registered Nurse Advanced Practice — C-NET
Which blueprint applies, and when did it take effect?
This guide follows the CARN-AP Test Specifications labeled implemented 2026. ANCB identifies the update as completed in 2025 and implemented in 2026, without specifying a day or month. The linked handbook is revised January 2026. The handbook and blueprint were verified on October 10, 2026; ANCB and C-NET examination pages were checked again on October 27, 2026.
ANCB — Statistics & Studies · CARN-AP Test Specifications (Blueprint) — Implemented 2026 · CARN-AP Examination Handbook — Revised January 2026
How are the activity domains weighted?
The official weights are Assess & Diagnose 30%; Prescribe/Intervene 30%, divided into pharmacological 16% and nonpharmacological 14%; Educate 25%; Consult 10%; and Research, Ethics, & CQI 5%. The 60 concepts use an 18/18/15/6/3 allocation. Both the 20 questions and 20 flashcards use a 6/6/5/2/1 allocation.
How does the patient-problem axis relate to the activity domains?
The blueprint also assigns opioid use disorder 24%, alcohol use disorder 24%, stimulant use disorder 15%, co-occurring psychiatric/comorbid medical conditions 13%, other use disorders 9%, tobacco use disorder 8%, and cannabis use disorder 7%. These describe a second, overlapping axis rather than additional examination portions. Other disorders include prescription drugs, inhalants, hallucinogens, designer drugs, and process addictions. A short guide cannot exhaust that scope.
What passing criterion does the handbook report, and how should these practice questions be used?
The CARN-AP Examination Handbook revised January 2026 states a 77% passing criterion. Do not convert that percentage into an exact required number of correct answers using the approximate pilot-item count. These original single-best-answer learning exercises have editorial difficulty estimates and do not predict examination performance. The ANCB blueprint establishes examination scope; cited clinical guidelines and prescribing information support the clinical teaching.
CARN-AP Test Specifications (Blueprint) — Implemented 2026 · CARN-AP Examination Handbook — Revised January 2026
This guide addresses ANCB's Certified Addictions Registered Nurse-Advanced Practice examination, CARN-AP. CARN is a separate registered-nurse certification. CARN-AP is an advanced practice addiction nursing credential; it does not independently confer nurse practitioner licensure or prescribing authority. These independently authored learning materials are not endorsed by ANCB.
Outline used: CARN-AP Test Specifications (Blueprint), implemented 2026; ANCB identifies the update as completed in 2025 and implemented in 2026. Current linked CARN-AP Examination Handbook revised January 2026. Verified on 2026-10-10. The workbook's corrupted dash in 'Certified Addictions Registered Nurse – Advanced Practice' maps to ANCB's current CARN-AP examination; this is a typography correction, not a different credential. Assigned slug preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Assess & Diagnose30%
1.How does a substance-use timeline sharpen assessment?
A useful history connects the substance, amount, route, frequency, last exposure, recent changes, and symptoms over time. This establishes whether intoxication, withdrawal, medication effects, or another illness plausibly explains the presentation. Ask about prescribed medications and nonprescribed products because interactions and unexpected ingredients can change risk. Reconcile the history with examination findings and testing rather than allowing any single result to determine the diagnosis or immediate level of care.
Apply it
A patient reports anxiety after stopping daily stimulant use but also recently reduced heavy alcohol intake. Build separate exposure timelines, assess alcohol withdrawal risk and vital signs, and avoid attributing every symptom to the stimulant crash.
Common pitfall: Recording only the preferred drug misses overlapping withdrawal and interaction risks. A positive test cannot establish which exposure is causing the current symptoms.
ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine · ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
2.How is opioid use disorder diagnosed and graded?
Opioid use disorder requires a problematic pattern causing clinically significant impairment or distress, with at least two of 11 criteria within 12 months: using more or longer than intended; unsuccessful efforts to reduce use; substantial time obtaining, using, or recovering; craving; failure to fulfill major obligations; continued use despite interpersonal problems; giving up important activities; recurrent hazardous use; continued use despite a related physical or psychological problem; tolerance; and withdrawal or use to avoid withdrawal. Severity is mild with 2–3 criteria, moderate with 4–5, and severe with 6 or more. Tolerance and withdrawal do not count when opioids are taken solely under appropriate medical supervision.
Apply it
Within one year, a patient repeatedly uses nonprescribed opioids longer than intended, unsuccessfully tries to stop, reports craving, and repeatedly misses work because of use. These establish four criteria and moderate OUD. If recurrent hazardous use and continued use despite a known opioid-related illness are also established, six criteria indicate severe OUD. A patient taking opioids solely as appropriately supervised treatment who has only tolerance and withdrawal does not meet OUD criteria on those findings.
Common pitfall: Count distinct criteria within the same 12-month period rather than counting every episode as another criterion. A positive drug test does not establish OUD, and expected tolerance or withdrawal during appropriate medical treatment must not inflate the diagnosis or severity.
ASAM — Opioid Use Disorder in Pregnancy · asam_engagement-and-retention-of-nonabstinent-patients_final_082624.pdf
3.When does a presumptive result need definitive testing?
Immunoassay results are presumptive because assay thresholds, cross-reactivity, and incomplete drug coverage can produce misleading findings. Definitive testing identifies specific substances more precisely and is particularly useful when a result is disputed, unexpected, or would drive a consequential treatment decision. First discuss medications, exposures, and the laboratory's assay characteristics. A clinically important discrepancy warrants clarification rather than an automatic accusation, punishment, or abrupt change in an otherwise effective treatment plan.
Apply it
A patient taking a prescribed medication disputes an unexpected amphetamine screen. Review possible cross-reactivity with the laboratory and obtain appropriate definitive testing before making a consequential diagnosis or changing the patient's addiction treatment.
Common pitfall: Repeating the same screening assay may reproduce the same limitation. Definitive testing should target the clinical discrepancy rather than becoming an indiscriminate panel.
ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine
4.Why can an opioid screen miss fentanyl exposure?
A routine opiate immunoassay commonly targets morphine-related compounds and may not reliably detect fentanyl, methadone, buprenorphine, or other opioids requiring separate assays. A negative result therefore has meaning only after confirming the panel's targets and sensitivity. In suspected overdose, respiratory status and clinical findings drive immediate care. Targeted testing can clarify exposure later, but an assay limitation must never delay ventilation support or administration of an opioid overdose reversal medication.
Apply it
A patient is unresponsive with slow breathing after using a powder sold as cocaine. The routine opiate screen is negative. Treat the suspected opioid overdose immediately and determine whether fentanyl-specific testing is available.
Common pitfall: Treating an opiate screen as a comprehensive opioid screen falsely excludes exposure. The assay name alone may conceal important gaps in coverage.
ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine · SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
5.Why does cannabis detection differ from driving impairment?
Cannabis can impair reaction time, coordination, judgment, and perception needed for safe driving. A urine metabolite result establishes exposure within a detection window, which can extend beyond the period of acute effects. It cannot reliably determine current driving fitness or the precise time of consumption. Assess recent use, symptoms, co-use of alcohol or other drugs, and observed function. Safety counseling should address impairment directly rather than treating a laboratory threshold as clearance.
Apply it
A patient with a positive cannabis urine test asks whether the result means they are currently impaired. Separate exposure detection from functional assessment, then discuss avoiding driving after use and the added impairment from alcohol.
Common pitfall: Neither a positive urine result nor a person's confidence provides a reliable measure of driving safety. Laboratory detection and functional impairment answer different questions.
CDC — Cannabis and Driving · ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine
6.Which findings predict complicated alcohol withdrawal?
Withdrawal risk depends on more than the current symptom score. Important predictors include prior withdrawal seizures or delirium, repeated withdrawal episodes, prolonged heavy regular consumption, significant medical illness, marked autonomic activation, and physiological dependence on other GABAergic drugs. Several risk factors together increase concern. Assess anticipated progression and available monitoring before selecting a setting. A patient who currently appears comfortable can still need preventive treatment and a more closely monitored level of care.
Apply it
A patient has mild tremor after reducing alcohol but reports two previous withdrawal seizures and has an acute infection. Recognize substantial prospective risk and arrange monitored management rather than relying on the mild presentation.
Common pitfall: A low symptom score describes the present assessment, not the entire future course. Prior complicated withdrawal remains important even before severe symptoms appear.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
7.When is CIWA-Ar an unreliable guide?
CIWA-Ar quantifies alcohol withdrawal symptoms in an appropriate patient; it is not a diagnostic test. Several items require reliable self-report, so delirium, severe cognitive impairment, communication barriers, and some critical illnesses undermine its use. Pain, anxiety, infection, or other withdrawal syndromes can also inflate scores. Interpret findings clinically and select an assessment approach suited to the patient's condition. In delirium, use objective monitoring and an appropriate delirium or sedation instrument instead.
Apply it
A disoriented inpatient cannot answer questions about nausea or perceptual disturbances. Assess causes of delirium, monitor objective findings, and use a suitable institutional protocol rather than recording guessed CIWA-Ar responses to trigger medication.
Common pitfall: A completed scale is not necessarily a valid scale. Guessing subjective answers creates false precision and may promote either excessive sedation or inadequate treatment.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
8.How can alcohol withdrawal occur with a positive alcohol level?
Alcohol withdrawal follows a substantial reduction in exposure relative to a dependent person's accustomed level; complete elimination of alcohol is not required. A patient can therefore develop tremor, autonomic activation, or other withdrawal manifestations while alcohol remains measurable. The level neither confirms nor excludes withdrawal. Examine the trajectory of intake and symptoms, prior withdrawal history, and competing explanations. A positive concentration must not postpone treatment when the clinical assessment supports withdrawal risk.
Apply it
A patient who usually drinks throughout the day develops sweating and tremor after sharply cutting intake. Alcohol remains detectable. Assess and manage withdrawal risk while also evaluating other causes of autonomic activation.
Common pitfall: Waiting for an alcohol concentration of zero can allow progression. Conversely, detectable alcohol does not prove that every abnormal finding is caused by withdrawal.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
9.Which findings make suspected opioid overdose immediately actionable?
Markedly slowed or absent breathing and inability to awaken are critical opioid overdose warning signs. Pinpoint pupils may support the assessment but are not required, particularly with mixed exposures. The immediate threat is inadequate ventilation and oxygenation. Activate emergency help, provide breathing support or CPR as indicated, and administer an opioid overdose reversal medication. Do not wait for toxicology confirmation, a complete exposure history, or certainty about the contents of the substance used.
Apply it
A companion reports that a person became unresponsive after using a counterfeit tablet. Breathing is infrequent and noisy. Begin emergency overdose response immediately, even though the tablet's contents and the person's medication history are unknown.
Common pitfall: Assuming noisy breathing means adequate breathing delays rescue. Snoring or gurgling in an unresponsive person can accompany a life-threatening overdose emergency.
SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
10.When does stimulant intoxication require emergency medical evaluation?
Stimulants increase sympathetic activity and can produce severe hypertension, tachycardia, hyperthermia, seizures, and cardiovascular complications. Chest pain, significant hyperthermia, altered consciousness, or escalating agitation are medical warning signs rather than routine symptoms to observe casually. Assessment should consider acute coronary syndromes and other serious causes according to the presentation. A calming environment may help, but it does not replace medical stabilization, appropriate monitoring, or emergency transfer when dangerous complications are suspected.
Apply it
After methamphetamine use, a patient reports pressure-like chest pain and is markedly tachycardic. Arrange emergency medical assessment and monitoring instead of attributing the pain to panic and continuing a routine counseling appointment.
Common pitfall: Young age does not exclude serious stimulant-associated cardiovascular illness. Labeling chest pain as anxiety before evaluating dangerous causes can miss a time-sensitive complication.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
11.Why does a stimulant crash require suicide-risk reassessment?
As stimulant intoxication wanes and acute withdrawal develops, dysphoria, depression, fatigue, and suicidal thinking can emerge or worsen. Reduced agitation does not necessarily indicate improved psychiatric safety. Reassess suicidal thoughts, intent, behavior, psychosis, and the person's ability to remain safe as the clinical state changes. Immediate safety needs determine disposition; longer-term diagnostic clarification follows stabilization. Persistent depression also deserves reassessment because substance-related and independent psychiatric conditions can coexist.
Apply it
A patient becomes quieter after prolonged cocaine use but now says life is hopeless and describes thoughts of dying. Repeat the suicide assessment and determine safe disposition instead of assuming sleep and discharge are sufficient.
Common pitfall: A calm appearance can obscure worsening depression. Risk assessment performed during intoxication does not automatically remain valid throughout withdrawal and early recovery.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
12.Which suicidal thoughts require an immediate safety response?
Current thoughts of killing oneself require urgent evaluation and protection from being left alone while safety is assessed. Ask directly about frequency, plan, intent, access to means, prior attempts, and supports. A detailed plan and access to the proposed method heighten concern, but the absence of a plan does not establish safety. Use the assessment to determine disposition and means-safety actions. A promise or contract to avoid self-harm is not a substitute.
Apply it
During an addiction visit, a patient reports current suicidal thoughts and accessible medications they considered taking. Keep the patient accompanied, arrange urgent psychiatric evaluation, and address access to the medications as part of immediate safety.
Common pitfall: Completing a routine referral without arranging immediate safety leaves a critical gap. A reassuring promise cannot replace assessment, supervision, and an appropriate disposition.
NIMH — Adult Outpatient Brief Suicide Safety Assessment Guide
13.How does benzodiazepine dependence differ from a use disorder?
Physical dependence is a physiological adaptation that can develop during regular prescribed benzodiazepine use. Withdrawal after dose reduction does not by itself establish a benzodiazepine use disorder. A use disorder involves a problematic pattern with clinically significant impairment or distress, assessed beyond expected adaptation. The distinction matters because dependent patients can experience severe withdrawal even when they have taken medication as directed. Evaluate benefits, harms, patterns of use, and withdrawal risk without stigmatizing the patient.
Apply it
A patient taking prescribed clonazepam consistently develops tremor after missed doses but reports no compulsive use or associated impairment. Recognize possible physical dependence, assess the full pattern, and plan safe medication management without assuming addiction.
Common pitfall: Using withdrawal alone to diagnose a use disorder confuses adaptation with behavioral pathology. The opposite error is assuming prescribed use eliminates withdrawal danger.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
14.Which symptoms support cannabis withdrawal?
After stopping or substantially reducing sustained cannabis use, irritability, anxiety, sleep difficulty, reduced appetite, restlessness, depressed mood, and physical discomfort can form a withdrawal pattern. Establish the temporal relationship and assess severity, functional effects, other substances, and psychiatric symptoms. The Marijuana Withdrawal Symptom Checklist can help organize symptom monitoring, but a checklist does not replace differential assessment. Severe confusion, seizures, or major autonomic instability should prompt investigation of another or additional cause.
Apply it
A patient stops daily cannabis use and reports irritability, poor sleep, reduced appetite, and restlessness. Track the symptoms and their timing, while checking for concurrent alcohol or sedative reduction and evaluating significant mood or safety concerns.
Common pitfall: Calling every symptom cannabis withdrawal can miss dangerous concurrent withdrawal. A characteristic cluster supports assessment but does not exclude medical or psychiatric illness.
15.What distinguishes a reactive HCV antibody from current infection?
A reactive hepatitis C antibody result indicates past or current exposure, or occasionally biological false positivity; it does not establish current viremia. HCV RNA testing determines whether current infection is present. A reactive antibody with detected RNA supports current infection and linkage to care. A reactive antibody with undetected RNA usually indicates no current infection. Recent exposure, suspected acute infection, or other clinical circumstances may require additional testing rather than relying on antibody alone.
Apply it
An addiction clinic receives a reactive HCV antibody result for a patient with prior injection exposure. Obtain reflex or follow-up HCV RNA testing before describing the patient as currently infected or making treatment decisions.
Common pitfall: Treating antibody positivity as active hepatitis confuses exposure with current infection. Conversely, an early negative antibody result may not exclude a recent infection.
16.Why is opioid and sedative co-use a distinct assessment priority?
Opioids combined with benzodiazepines, alcohol, or other sedating substances can increase respiratory depression and overdose risk. Ask specifically about prescribed and nonprescribed sedatives, timing, amount, and recent changes rather than recording each substance in isolation. Assess alertness, breathing, prior overdose, and access to reversal medication. The response should reduce immediate danger while preserving treatment engagement. Physiological dependence on a sedative also changes how safely that medication can be reduced or stopped.
Apply it
A patient receiving opioid use disorder treatment reports taking borrowed benzodiazepines to sleep. Assess current sedation and breathing, discuss overdose prevention, and coordinate a safer plan rather than abruptly ending addiction care or ignoring the combination.
Common pitfall: Simply instructing a dependent patient to stop sedatives immediately can create another emergency. Interaction risk and withdrawal risk must be addressed together.
SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC · ASAM — Benzodiazepine Tapering
17.How should unexpected designer-drug exposure change testing?
Routine drug panels cover selected analytes rather than every psychoactive product. Novel substances and changing product contents can fall outside those targets, so a negative panel cannot exclude clinically significant exposure. Begin with the toxidrome, physiological instability, exposure history, and available collateral information. Consult the laboratory about targeted or definitive testing when the answer would change care. Stabilization remains clinical, and a product's advertised name should not be treated as a verified ingredient list.
Apply it
A patient develops severe agitation after using a product sold as a designer stimulant, but the routine panel is negative. Address the physiological risk and ask the laboratory what additional testing can meaningfully clarify the exposure.
Common pitfall: Ordering a larger routine panel without checking its targets may add cost without answering the question. Negative testing cannot validate an unknown product's safety.
ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine · ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
18.How does timing help distinguish stimulant-related psychiatric symptoms?
Assess whether depression, anxiety, psychosis, or sleep disturbance preceded stimulant use, appeared during intoxication, emerged during withdrawal, or persisted beyond the expected course. Prior episodes during sustained nonuse and collateral history help distinguish an independent condition from a substance-related syndrome. Timing informs the differential but does not justify withholding urgent treatment. Psychosis, suicidality, and severe functional impairment require active management while diagnostic certainty develops through follow-up and repeated assessment over time.
Apply it
A patient reports paranoia after a stimulant binge but also describes similar episodes during a prolonged period without use. Obtain collateral and longitudinal history, address present safety, and evaluate both stimulant-related and independent psychiatric explanations.
Common pitfall: Assuming all psychiatric symptoms will resolve with abstinence can delay care. Diagnosing a lifelong disorder from one intoxicated encounter can also misrepresent the course.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
Prescribe/Intervene30% (pharmacological 16%; nonpharmacological 14%)
19.Why are benzodiazepines first-line for significant alcohol withdrawal?
Alcohol withdrawal reflects excessive central nervous system excitation after adaptation to sustained alcohol exposure. Benzodiazepines enhance GABA-mediated inhibition and reduce withdrawal manifestations, including the risk of seizures and delirium. Selection, administration strategy, and monitoring depend on severity, risk factors, comorbidities, and the care setting. Symptom-triggered treatment is useful when reliable assessment and trained monitoring are available. Respiratory status and sedation require attention, especially with other depressants or medically vulnerable patients receiving repeated treatment.
Apply it
A patient has moderate alcohol withdrawal with reliable assessment available in a monitored setting. Use an evidence-based benzodiazepine protocol and reassess symptoms, sedation, and breathing rather than treating tachycardia alone with a cardiovascular medication.
Common pitfall: Suppressing pulse or blood pressure does not adequately treat withdrawal neuroexcitation. Adjunctive autonomic medications cannot replace appropriate treatment for seizure and delirium prevention.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
20.How does liver disease affect alcohol-withdrawal medication selection?
Lorazepam or oxazepam is commonly preferred for alcohol withdrawal in significant hepatic impairment. Both undergo glucuronidation and do not produce clinically active metabolites. Glucuronidation is relatively preserved compared with the hepatic oxidative pathways used by diazepam and chlordiazepoxide, whose active metabolites can accumulate and prolong sedation. This difference reduces accumulation risk but does not eliminate benzodiazepine toxicity. Treatment still requires repeated assessment of withdrawal severity, alertness, respiratory rate, and oxygenation, with dosing adjusted to clinical response.
Apply it
For a patient with cirrhosis and clinically significant alcohol withdrawal, consider lorazepam or oxazepam in an appropriately monitored setting. Increasing somnolence after repeated doses should prompt reassessment for medication accumulation, respiratory depression, hepatic encephalopathy, and other causes of altered cognition rather than automatic additional dosing.
Common pitfall: A routine diazepam or chlordiazepoxide regimen can cause prolonged sedation when oxidative metabolism is impaired. Conversely, withholding adequate withdrawal treatment can permit seizures or withdrawal delirium. Selecting lorazepam or oxazepam does not remove the need for close sedation and respiratory monitoring.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
21.When is parenteral thiamine particularly important?
Thiamine supplementation addresses deficiency risk in alcohol withdrawal care and helps prevent Wernicke encephalopathy. Parenteral administration is particularly appropriate with poor nutrition, malabsorption, or severe withdrawal complications, when oral delivery may be unreliable. Confusion, gait disturbance, or ocular findings increase concern for Wernicke encephalopathy and warrant prompt evaluation and treatment. Necessary glucose should not be delayed: ASAM permits thiamine and glucose in either order or concurrently when clinically indicated for the patient's condition.
Apply it
A poorly nourished patient with heavy alcohol use presents with hypoglycemia and confusion. Treat the hypoglycemia promptly and provide appropriate thiamine, while evaluating neurological findings and arranging the level of monitoring the presentation requires.
Common pitfall: Waiting to give urgently needed glucose until thiamine arrives can prolong hypoglycemia. Routine oral supplementation may be inadequate when absorption or acute neurological illness is concerning.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
22.Which renal findings change acamprosate eligibility?
Acamprosate supports maintenance of alcohol abstinence in patients who are abstinent when treatment begins and should accompany psychosocial support. It does not treat acute alcohol withdrawal. Because acamprosate is cleared through the kidneys, creatinine clearance determines eligibility and dosing. Creatinine clearance of 30 mL/min or less is a contraindication. At exactly 30 mL/min, the contraindication takes precedence over the overlapping wording in the label's dose-reduction section. Reduced dosing of 333 mg three times daily applies to values above 30 through 50 mL/min.
Apply it
A patient completing withdrawal treatment has a calculated creatinine clearance of 40 mL/min: if otherwise appropriate, use the reduced regimen. A patient with creatinine clearance of exactly 30 mL/min is ineligible for acamprosate; prescribing the reduced dose does not resolve the contraindication.
Common pitfall: Do not interpret the label's dose-reduction range as permission to prescribe at exactly 30 mL/min. Choosing acamprosate because of hepatic concerns must still include renal assessment, and abstinence maintenance treatment cannot replace medication needed for active withdrawal.
23.Why must opioid exposure be assessed before extended-release naltrexone?
Naltrexone antagonizes opioid receptors and can precipitate severe withdrawal in a person who remains opioid dependent. The extended-release label recommends an opioid-free period, generally at least 7–10 days for previously dependent users of short-acting opioids; vulnerability may last longer after methadone or buprenorphine. History, clinical assessment, and appropriate testing inform safety, but no single test guarantees a sufficient interval. Current opioid analgesic use, dependence, or acute opioid withdrawal precludes routine administration.
Apply it
A patient requesting extended-release naltrexone stopped short-acting opioids three days ago and still has withdrawal symptoms. Defer the injection, assess treatment options, and develop a safe initiation plan rather than relying on one negative screening result.
Common pitfall: A negative urine screen or tolerated challenge does not eliminate every risk of precipitated withdrawal. Medication timing must account for the opioid and the patient's condition.
24.How can buprenorphine both treat and precipitate opioid withdrawal?
Buprenorphine has high affinity for the mu-opioid receptor but only partial agonist activity. It can suppress withdrawal and craving, yet displacing a full agonist before sufficient withdrawal develops can abruptly reduce receptor activation and precipitate withdrawal. Conventional initiation therefore depends on the exposure history and objective withdrawal assessment, not elapsed time alone. The appropriate induction approach requires individualized planning, particularly when the opioid supply is uncertain or longer-acting exposures may complicate the expected course.
Apply it
A pregnant patient requests buprenorphine shortly after using a full-agonist opioid and has no objective withdrawal. Explain the displacement risk and arrange a clinically appropriate initiation plan instead of assuming partial agonism makes immediate conventional dosing harmless.
Common pitfall: High receptor affinity does not mean full agonist activity. A clock-based rule without clinical assessment may misjudge readiness when exposure duration or drug contents are uncertain.
25.Why is opioid agonist treatment preferred during pregnancy?
For opioid use disorder during pregnancy, methadone or buprenorphine treatment is preferred to withdrawal management because return to opioid use creates substantial maternal and fetal risk. Treatment stabilizes opioid exposure and supports ongoing prenatal and addiction care. Medication selection considers the patient's prior response, clinical needs, preferences, and treatment access. Neonatal opioid withdrawal is an anticipated, treatable possibility rather than a reason to withhold effective maternal treatment or pursue an unsafe abrupt medication discontinuation.
Apply it
A pregnant patient stable on opioid agonist treatment wants to stop immediately to prevent neonatal withdrawal. Discuss the risks of return to use and coordinate continued treatment with prenatal care and a neonatal planning team.
Common pitfall: Focusing only on neonatal withdrawal overlooks the risks of destabilizing maternal treatment. Pregnancy does not make medically supervised withdrawal the preferred routine approach to opioid use disorder.
26.How should a benzodiazepine taper respond to withdrawal symptoms?
A benzodiazepine taper should be gradual, collaborative, and adjusted to the patient's response. The joint guideline describes initial reductions of about 5–10% every 2–4 weeks as a general starting approach, with substantial individual variation and slower progress when needed. Significant symptoms may justify pausing or slowing reductions. Assess withdrawal risk, recurrence of the treated condition, and other causes of symptoms. A taper is a clinical process rather than a fixed calendar that must be completed regardless of harm.
Apply it
A patient develops marked insomnia and anxiety after a planned reduction in long-term benzodiazepine treatment. Reassess symptoms and safety, consider slowing or pausing the taper, and continue treating the underlying condition alongside withdrawal management.
Common pitfall: A published starting pace is not a mandatory schedule. Abrupt discontinuation or accelerating reductions because the patient struggles can increase the risk of severe withdrawal.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
27.Why combine a nicotine patch with short-acting replacement?
A nicotine patch supplies a relatively steady level that reduces background withdrawal, while gum or lozenges can address breakthrough cravings. These complementary roles can improve cessation support compared with relying on one form alone. Select appropriate products and instructions for the patient's smoking pattern and medical circumstances, and combine medication with counseling. Review adherence and technique when cravings persist rather than assuming the treatment has failed or that using two replacement forms necessarily represents unsafe duplication.
Apply it
A patient using a patch has fewer morning cravings but still struggles during work breaks. Review patch use and add an appropriate short-acting nicotine replacement option, with instructions and counseling focused on predictable triggers.
Common pitfall: Treating every craving as evidence that the patch is useless misses the role of short-acting support. Product technique and adherence also affect clinical benefit.
CDC — How to Combine Quit Smoking Medicines · CDC — Clinical Interventions to Treat Tobacco Use and Dependence Among Adults
28.Which findings exclude disulfiram despite an abstinence goal?
Disulfiram inhibits aldehyde dehydrogenase, causing acetaldehyde accumulation after alcohol exposure. It may support an informed abstinence plan but does not treat acute withdrawal. The U.S. label contraindicates treatment in severe myocardial disease or coronary occlusion and psychosis, and prohibits administration with current or recent metronidazole or alcohol-containing preparations. It also identifies hypersensitivity to disulfiram or other thiuram derivatives as a contraindication. Administration requires at least 12 hours of alcohol abstinence, informed consent, and a feasible adherence and monitoring plan.
Apply it
An abstinence-oriented patient who understands alcohol avoidance has no identified contraindication and has been alcohol-free for 24 hours; disulfiram may be considered after full assessment. A similarly motivated patient with severe myocardial disease should not receive it. Motivation, supervision, and a longer abstinence interval do not remove that contraindication.
Common pitfall: An abstinence goal alone does not establish eligibility. Do not administer disulfiram during intoxication, before the label's minimum 12-hour abstinence interval, secretly, or with a prohibited exposure such as metronidazole. Its alcohol reaction is a potentially serious hazard rather than a harmless deterrent.
29.How does contingency management reinforce stimulant treatment goals?
Contingency management uses timely, tangible reinforcement linked to a clearly defined and verified behavior, such as attendance or stimulant-negative specimens. It applies operant learning principles rather than relying on advice alone. The ASAM/AAAP guideline identifies it as the current standard of care for stimulant use disorder and recommends it as a primary component of treatment. Effective implementation requires transparent targets, dependable verification, and reinforcement delivered consistently enough for the behavioral connection to remain meaningful.
Apply it
A clinic wants to improve engagement in stimulant treatment. Develop a transparent program that provides prompt reinforcement for verified attendance or agreed treatment targets, and integrate it with other appropriate behavioral and clinical services.
Common pitfall: A reward unrelated to a defined behavior is not a well-specified contingency. Delayed, inconsistent reinforcement weakens the connection the intervention is designed to create.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
30.What does cognitive behavioral treatment add to stimulant care?
Cognitive behavioral treatment helps patients recognize relationships among triggers, thoughts, emotions, and stimulant use, then practise alternative responses. Skills can include anticipating high-risk situations, managing cravings, solving practical problems, and responding to a lapse without abandoning treatment. The stimulant guideline supports CBT alongside contingency management when available. Its value lies in structured skills development and rehearsal, not simply explaining drug harms. Treatment should connect the skills to the patient's actual environment and current goals.
Apply it
A patient repeatedly uses cocaine after conflicts at work. Map the trigger and immediate thoughts, rehearse an alternative response, and plan how to leave the high-risk situation while continuing the broader stimulant treatment program.
Common pitfall: Giving general advice to avoid stress is not a substitute for skills practice. A lapse should prompt analysis and plan revision rather than automatic treatment termination.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
31.Why should alcohol use disorder treatment begin during withdrawal care?
Withdrawal management addresses acute physiological instability but does not by itself treat the continuing pattern of alcohol use disorder. ASAM recommends using the withdrawal episode to initiate or engage ongoing treatment as cognitive status permits. Discuss treatment goals, appropriate medications, psychosocial care, and a concrete follow-up plan. A successful transition includes access and continuity rather than merely advising abstinence at discharge. The immediate withdrawal regimen and the continuing treatment plan serve different but connected clinical purposes.
Apply it
A patient's withdrawal symptoms improve before discharge. Discuss alcohol use disorder medication options and preferences, arrange follow-up, and confirm access to continuing care rather than ending treatment when the withdrawal protocol is completed.
Common pitfall: Calling detoxification a complete treatment can create a dangerous gap. Clinical stabilization should create an opportunity for continuing care rather than mark its endpoint.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
32.Which changes make ambulatory alcohol withdrawal care unsafe?
Ambulatory management requires a suitable initial risk profile, reliable reassessment, and a clear transfer plan. Escalating agitation, persistent vomiting, hallucinations, confusion, seizures, unstable vital signs, worsening medical illness, or excessive sedation can exceed the setting's capabilities. Assess the direction of change and the resources available rather than waiting for a predetermined appointment. A supportive home environment helps but cannot compensate for severe complications. Transfer is a planned safety response when the patient's needs increase.
Apply it
A patient in ambulatory withdrawal care develops confusion and persistent vomiting between scheduled visits. Arrange prompt transfer to a more intensive setting instead of simply increasing a home medication supply and waiting for tomorrow's reassessment.
Common pitfall: Reliable family supervision cannot make severe withdrawal safe at home. A treatment setting must match current clinical needs, not only the original assessment.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
33.How can behavioral treatment support benzodiazepine reduction?
A taper can uncover both withdrawal symptoms and the anxiety or insomnia for which the benzodiazepine was originally prescribed. Behavioral interventions tailored to the underlying condition, including CBT or CBT for insomnia, can improve the patient's ability to tolerate reduction and sustain functioning. Start or optimize these supports alongside the taper rather than expecting dose changes alone to solve the original problem. Treatment remains collaborative, with symptom monitoring used to adjust the pace and identify other needs.
Apply it
A patient fears benzodiazepine reduction because insomnia previously disrupted employment. Arrange CBT for insomnia, review sleep-related behaviors, and agree on symptom follow-up while creating a gradual taper that can be adjusted as necessary.
Common pitfall: Removing a medication without addressing its original indication leaves a predictable treatment gap. Behavioral support complements individualized tapering rather than justifying an unnecessarily rapid schedule.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
34.When should psychosocial needs affect opioid treatment access?
Psychosocial assessment identifies needs such as housing, psychiatric care, transportation, family support, and behavioral treatment. These findings should shape offered services and coordination. ASAM's 2024 Engagement and Retention guidance states that counseling participation should not be required for medication initiation or continuation. Declining counseling or lacking access should therefore not delay appropriate opioid use disorder pharmacotherapy. During pregnancy, methadone or buprenorphine is recommended over withdrawal management alone. Offer psychosocial care alongside medication, adapting services to the patient's preferences and practical circumstances.
Apply it
A pregnant patient requests opioid use disorder medication but cannot attend a counseling group because transportation is unavailable. Arrange appropriate methadone or buprenorphine treatment without requiring group attendance first. Offer accessible individual, remote, or community support and revisit psychosocial needs during follow-up.
Common pitfall: Requiring counseling attendance can delay effective medication when transportation, service availability, or patient preference prevents participation. Offer accessible psychosocial support while initiating or continuing appropriate pharmacotherapy.
ASAM — Opioid Use Disorder in Pregnancy · asam_engagement-and-retention-of-nonabstinent-patients_final_082624.pdf
35.How should symptom monitoring guide cannabis withdrawal support?
A structured symptom record can identify which cannabis withdrawal problems interfere most with daily functioning, including sleep disturbance, irritability, anxiety, and appetite reduction. Use repeated observations to evaluate the course and tailor supportive care rather than responding to an undifferentiated complaint of feeling unwell. Reassess unexpected deterioration, severe mood symptoms, or concurrent substance withdrawal. The NIDA checklist is a symptom instrument; it does not establish that a particular medication is effective or appropriate for treatment.
Apply it
A patient stopping daily cannabis use identifies insomnia as the main barrier to work attendance. Track sleep and other symptoms, address practical sleep supports, and reassess mood and other substance exposure if the course becomes atypical.
Common pitfall: A symptom checklist does not validate a medication regimen. Improvement or worsening should be interpreted with the clinical history, functioning, and competing explanations.
36.When is de-escalation useful in stimulant-related agitation?
A low-stimulation environment, calm communication, and verbal de-escalation can reduce distress during stimulant-related agitation when the patient can engage safely. Assess physiological instability, psychosis, and risk of harm at the same time. Behavioral measures should not delay medication, monitoring, or transfer when severe agitation or medical complications require them. The aim is to reduce stimulation and preserve cooperation while maintaining a clear threshold for additional treatment based on the patient's evolving condition.
Apply it
An anxious patient after stimulant use is pacing but can converse and has stable observations. Reduce environmental stimulation and use calm engagement while monitoring; escalate promptly if agitation, psychosis, temperature, or cardiovascular findings worsen.
Common pitfall: Insisting on verbal calming despite severe instability can delay necessary treatment. Restraint or confrontation without de-escalation may also intensify distress and complicate safe assessment.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
Educate25%
37.What should a bystander do first during suspected opioid overdose?
Teach a simple emergency sequence: recognize unresponsiveness and abnormal breathing, activate emergency help, give an opioid overdose reversal medication, and provide breathing support or CPR as indicated. Follow emergency dispatcher and product instructions. Stay with the person and monitor their response. The immediate objective is restoring adequate breathing, not merely making the person fully awake. Emergency assessment remains necessary because exposure contents, co-ingestants, and the duration of drug effects may be uncertain.
Apply it
A patient asks what their partner should do if they cannot be awakened after opioid use. Rehearse recognizing abnormal breathing, calling emergency services, administering naloxone, and supporting breathing according to available training and dispatcher instructions.
Common pitfall: Walking the person around, cold showers, or waiting for spontaneous recovery delays effective rescue. A reversal kit is most useful when companions know how to respond.
SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
38.Why can breathing worsen again after naloxone works?
Naloxone can wear off before the opioid responsible for overdose, allowing respiratory depression to recur. Some overdoses also require repeated administrations according to product instructions while emergency assistance is on the way. Continue observing breathing, support ventilation as needed, and remain with the person. A brief return to wakefulness is not proof that the emergency has ended. Teach companions to respond to breathing rather than assuming that one administered dose guarantees lasting protection.
Apply it
A person wakes after naloxone but later becomes difficult to arouse and breathes slowly again. The companion should continue emergency response, administer another dose according to instructions, and support breathing while awaiting professional help.
Common pitfall: Leaving after the first apparent recovery creates a gap when recurrent sedation may occur. Naloxone response does not eliminate the need for emergency care.
SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
39.Why is return to opioid use dangerous after a period without use?
Opioid tolerance decreases during periods of reduced or absent exposure, such as hospitalization, incarceration, or treatment interruption. A previously tolerated amount may then cause fatal respiratory depression. Unpredictable potency further increases risk, so prior experience cannot establish a safe amount. Discuss overdose prevention before transitions, provide access to reversal medication, and support continuing treatment. Education should explain the mechanism directly while helping the patient make a practical safety and follow-up plan.
Apply it
A patient leaving a period of enforced abstinence plans to resume their former opioid amount. Explain reduced tolerance, arrange overdose prevention resources and treatment linkage, and include trusted supports in the plan when the patient agrees.
Common pitfall: Describing someone as experienced can create false reassurance. Familiarity with prior use does not preserve tolerance or predict the strength of a new supply.
SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
40.How should patients understand opioid and alcohol interactions?
Alcohol and other sedating substances can intensify opioid-related sedation and respiratory depression. Explain that combining drugs changes risk even when each has previously been used without an overdose. Include prescribed sedatives in the discussion and ask patients to coordinate changes with their treatment team. Practical education includes recognizing abnormal breathing, ensuring reversal medication is accessible, and teaching companions an emergency response. Avoid implying that spacing substances by an arbitrary interval reliably eliminates the interaction.
Apply it
A patient assumes evening alcohol is safe because their opioid medication is prescribed. Explain the additive breathing risk, review all sedatives with the treatment team, and confirm that the patient and household understand overdose recognition and response.
Common pitfall: Legal or prescribed status does not prevent a dangerous interaction. Giving an unsupported waiting interval can imply a guarantee that the clinical evidence does not provide.
SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
41.Why offer overdose education to people using stimulants?
People who intend to use stimulants can encounter opioids through an unpredictable or contaminated drug supply and may have little opioid tolerance. Stimulant use therefore does not exclude opioid overdose risk. Discuss reversal medication, emergency recognition, avoiding solitary use, and available drug-checking resources. Explain that naloxone reverses opioid effects rather than stimulant toxicity. Severe chest pain, seizures, or hyperthermia still require emergency treatment even when an opioid reversal medication has also been administered.
Apply it
A patient who uses cocaine declines naloxone because they never intentionally use opioids. Explain unexpected opioid exposure, offer naloxone and response training, and discuss additional ways to reduce risk without implying that naloxone treats every stimulant complication.
Common pitfall: Counseling only people who identify as opioid users misses exposure risk. Conversely, carrying naloxone does not protect against all cardiovascular or temperature-related stimulant harms.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder · SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
42.What changes when xylazine may be present in an overdose?
Xylazine is a nonopioid sedative, so naloxone does not directly reverse its effects. Nevertheless, give naloxone when opioid exposure is possible because xylazine may occur with opioids and the opioid component remains treatable. Activate emergency services and prioritize breathing support. Persistent sedation after naloxone does not establish that no opioid was involved or that further care is unnecessary. Teach that rescue may require continuing support for more than one drug effect.
Apply it
A companion suspects xylazine in the substance used by an unresponsive person. They should administer naloxone for possible opioid effects, call emergency services, and support breathing rather than withholding naloxone because it cannot reverse xylazine itself.
Common pitfall: Concluding that naloxone is useless in mixed exposure overlooks the opioid component. Waiting for the person to awaken completely can distract from respiratory support.
SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
43.Why does extended-release naltrexone require overdose counseling?
Naltrexone blocks opioid effects but does not make overdose impossible. Attempting to overcome the blockade with large opioid amounts can be fatal. Reduced tolerance also increases vulnerability near the end of a dosing interval, after a missed injection, or after discontinuation. Explain these distinct risks and discuss access to an opioid overdose reversal medication. Patients should understand that the absence of a perceived opioid effect is not evidence that escalating use is safe.
Apply it
A patient receiving extended-release naltrexone asks whether taking enough opioid could produce an effect. Explain the danger of overcoming blockade and the increased vulnerability after treatment lapses, then review reversal medication access and emergency response.
Common pitfall: Describing receptor blockade as complete overdose protection creates false reassurance. Reduced tolerance remains relevant when blockade wanes or treatment is interrupted.
44.Which alcohol exposures matter during disulfiram treatment?
Disulfiram can cause an alcohol reaction from beverages and some alcohol-containing medicines, foods, or personal products. Teach patients to check ingredients and ask about uncertain products. The label warns that a reaction can occur for up to 14 days after the last dose. Explain the mechanism and possible seriousness rather than describing the reaction as a harmless deterrent. Patients should understand what symptoms require urgent help and why testing the medication with alcohol is unsafe.
Apply it
A patient stops disulfiram before a celebration and assumes drinking the next day is safe. Explain the persistent reaction risk and review the label's warning period, including alcohol-containing products the patient may not consider beverages.
Common pitfall: Skipping one dose does not reliably remove the reaction risk. Advising patients to test their sensitivity with a small drink exposes them to avoidable harm.
45.What should patients report during a benzodiazepine taper?
Teach patients to report new or worsening symptoms after dose reductions, including anxiety, insomnia, tremor, perceptual changes, and impaired functioning. Severe confusion or seizures require emergency assessment. Symptoms may reflect withdrawal, recurrence of the original condition, or another illness; the timing and pattern help the team distinguish them. Encourage contact before self-adjusting or abruptly stopping medication. A shared plan should state how symptoms are monitored and how the taper can be slowed or paused.
Apply it
A patient worries that reporting symptoms will be interpreted as failure. Explain that symptom reports guide safer adjustments, agree on a contact plan, and identify severe neurological symptoms that require immediate emergency evaluation rather than routine follow-up.
Common pitfall: Presenting taper discomfort as something the patient must simply endure discourages useful reporting. Symptoms should inform assessment rather than automatically trigger either abandonment or acceleration.
Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
46.How do you calculate U.S. standard drinks?
A U.S. standard drink contains about 14 grams of pure alcohol. Typical equivalents are 12 fluid ounces of 5% beer, 5 fluid ounces of 12% wine, or 1.5 fluid ounces of 40% spirits. Container size and alcohol concentration both matter; one container need not equal one drink. For comparison with 5% beer, multiply the beer's ounces by its alcohol percentage and divide by 12 times 5. Other countries may define a standard drink differently.
Apply it
A patient reports one 16-ounce can of 9% beer each evening. Calculate 16 × 9 ÷ 60 = 2.4 U.S. standard drinks, then use that amount rather than one can when discussing the drinking history.
Common pitfall: Counting containers underestimates exposure when servings are large or strong. Always identify the country's standard-drink definition before applying a numerical conversion.
47.How should cannabis users plan for driving safety?
Cannabis can impair reaction time, coordination, decision-making, and perception. Combining it with alcohol can increase impairment. Advise planning transportation that does not depend on driving after use, and explain that feeling confident does not prove unimpaired performance. Product strength, route, and individual response vary, so a universal waiting interval is not established here. A urine result cannot provide driving clearance. Make the discussion concrete by identifying when and how the patient will avoid driving.
Apply it
A patient plans to use cannabis at a gathering and drive home because the trip is short. Help arrange a sober driver or another transport option and discuss why distance and personal confidence do not remove impairment risk.
Common pitfall: Offering a fixed unsupported waiting time can create false certainty. Short trips still require the attention, judgment, and reaction time that cannabis can impair.
48.How does counseling make tobacco medication more useful?
Tobacco dependence treatment works best when behavioral support and medication are used together. Counseling helps patients identify triggers, plan alternatives, use medication correctly, and respond constructively to lapses. Medication reduces withdrawal and craving but does not automatically change routines or solve access barriers. Ask about the patient's specific difficult moments and teach a practical response. Continued follow-up allows technique, adherence, side effects, and preferences to be reviewed rather than assuming an unsuccessful attempt reflects insufficient motivation.
Apply it
A patient repeatedly smokes during the drive to work despite using cessation medication. Discuss the driving trigger, plan a replacement routine, review medication use, and arrange follow-up instead of simply repeating advice about the harms of smoking.
Common pitfall: Medication advice alone may leave a predictable behavioral trigger untouched. A lapse is an opportunity to revise treatment rather than evidence that further support is pointless.
CDC — Clinical Interventions to Treat Tobacco Use and Dependence Among Adults
49.Why does HCV cure need a continuing prevention plan?
Successful hepatitis C treatment does not provide immunity against reinfection. People with ongoing exposure risk benefit from counseling and access to harm-reduction services, including sterile injection equipment and substance use disorder treatment. Discuss sharing of preparation equipment as well as needles, and make prevention resources practically accessible. Education should explain that cure is valuable even when risk remains. Continued exposure calls for prevention and appropriate testing, not denial of treatment or assumptions that infection is inevitable.
Apply it
A patient completing HCV treatment believes cure means future injections cannot transmit hepatitis C. Explain reinfection risk, connect the patient with sterile equipment and addiction treatment resources, and agree on a follow-up testing plan.
Common pitfall: Treating cure as immunity leaves a preventable knowledge gap. Using ongoing risk to discourage treatment overlooks both the benefit of cure and available prevention services.
50.How should neonatal opioid withdrawal be explained to families?
Neonatal opioid withdrawal can follow prenatal opioid exposure, including prescribed methadone or buprenorphine treatment. Explain that the infant may need observation and treatment, and that neonatal withdrawal is expected and treatable rather than evidence of parental wrongdoing. Maternal treatment remains important because destabilization and return to opioid use create substantial risks. Discuss the neonatal plan with the obstetric and pediatric teams so families understand what monitoring and support may be needed after birth.
Apply it
A patient fears that neonatal monitoring means their prescribed treatment harmed the baby and wants to stop medication. Explain the purpose of observation and the benefits of stable maternal treatment, then arrange a conversation with the neonatal team.
Common pitfall: Promising that an infant will have no withdrawal is unsupported. Using frightening language about neonatal symptoms can drive unsafe maternal medication changes and disengagement.
51.Which stimulant warning signs should patients recognize?
Teach patients that chest pain, severe overheating, seizures, marked confusion, or escalating agitation after stimulant use require emergency medical help. These can signal cardiovascular, neurological, or temperature-related complications rather than a routine unpleasant experience. Encourage companions to recognize danger and act promptly. A person should not attempt to manage serious symptoms by taking an unprescribed sedative or using more substances. Education should pair symptom recognition with a clear plan for obtaining emergency assistance.
Apply it
A patient reports that friends usually wait out severe symptoms after stimulant use. Rehearse which findings require emergency help and how companions can call for assistance, stay present, and communicate known exposures to responders.
Common pitfall: Assuming a familiar drug cannot cause a new emergency is unsafe. Naloxone availability also does not replace medical care for stimulant-related chest pain or hyperthermia.
ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
Consult10%
52.How should extended-release naltrexone affect procedural pain planning?
Extended-release naltrexone can block opioid analgesia, so elective procedures require communication among the addiction clinician, procedural team, and pain or anesthesia service. Share the medication and injection date, anticipated pain needs, and the plan for continuing addiction care. The label describes regional and nonopioid approaches for emergency pain management. If opioid therapy is necessary, appropriately trained clinicians and a suitable monitored setting are required. Patients should not attempt to overcome the blockade themselves.
Apply it
A patient receiving monthly naltrexone is scheduled for surgery. With consent, communicate the last injection date to anesthesia and coordinate an analgesia and follow-up plan before the procedure rather than leaving the issue until postoperative pain develops.
Common pitfall: Simply increasing routine outpatient opioid doses can be ineffective and hazardous. Pain planning must also consider changing opioid sensitivity as receptor blockade wanes.
53.When should ongoing drug use delay HCV treatment linkage?
Active or recent drug use and concern about reinfection are not contraindications to hepatitis C treatment. Link patients with confirmed infection to an experienced treatment service while addressing practical barriers and offering harm reduction and addiction care. Coordination can improve access, adherence support, and follow-up without requiring an unsupported period of abstinence. Reinfection prevention and testing remain important, but the possibility of a future infection does not erase the benefit of treating the current one.
Apply it
A patient with detectable HCV RNA continues injecting and expects the referral to be refused. Explain that ongoing use does not automatically exclude treatment, arrange linkage, and coordinate sterile equipment access and substance use disorder services.
Common pitfall: An arbitrary abstinence prerequisite creates an avoidable barrier. Concern about reinfection should lead to prevention and follow-up rather than categorical denial of antiviral care.
54.Which test monitors HCV reinfection after cure?
HCV antibody commonly remains reactive after spontaneous clearance or successful treatment, making repeat antibody testing unsuitable for detecting reinfection. Use HCV RNA testing when assessing new infection in someone already antibody positive. AASLD/IDSA recommends at least annual RNA testing for people with recent injection drug use after clearance or cure, with additional evaluation as clinically indicated. Coordinate responsibility for testing and result follow-up so surveillance is not lost between addiction, primary care, and specialty services.
Apply it
A patient cured of HCV continues injecting and attends both primary care and addiction visits. Agree which team will order at least annual HCV RNA testing and manage results rather than repeating antibody tests at each service.
Common pitfall: A persistently reactive antibody does not demonstrate treatment failure or reinfection. Repeating it can generate confusion while failing to answer whether viremia has returned.
55.Which symptoms during disulfiram therapy require stopping treatment and urgent evaluation?
Disulfiram can cause serious hepatitis, including in patients without prior abnormal liver function. New jaundice or dark urine, especially with nausea, anorexia, fatigue, weakness, or malaise, raises concern for significant hepatic injury. Stop disulfiram and arrange urgent medical evaluation rather than waiting for routine monitoring or assuming an alcohol reaction. Obtain baseline liver testing before treatment; the U.S. label suggests follow-up liver testing at 10–14 days. Scheduled testing does not replace immediate action when warning symptoms appear.
Apply it
A patient taking disulfiram reports new dark urine, nausea, and yellow eyes. Stop disulfiram immediately, arrange urgent medical assessment and liver testing, and communicate the medication history to the evaluating clinician. Do not continue dosing while waiting for the next counseling appointment or scheduled laboratory check.
Common pitfall: Normal baseline results and absence of known liver disease do not eliminate hepatotoxicity risk. Merely arranging a prescribing review while treatment continues misses the immediate medication action required when serious hepatic injury is suspected.
DailyMed — Disulfiram Prescribing Information · Clinical guidelines for alcohol treatment - 10. Pharmacological interventions - Guidance - GOV.UK
56.Why does pregnancy require a coordinated opioid treatment plan?
Pregnancy-related opioid use disorder care connects addiction treatment, obstetric assessment, delivery planning, and neonatal care. Coordination helps maintain medication access, communicate relevant exposures, anticipate neonatal observation, and plan postpartum follow-up. Changes in location or clinical team should not inadvertently interrupt effective treatment. Use consent and appropriate information-sharing practices to support continuity. The aim is a workable sequence of care across settings, with responsibilities and access arranged before transitions rather than left to the patient alone.
Apply it
A pregnant patient will deliver at a hospital separate from the addiction clinic. Coordinate medication verification, obstetric and neonatal communication, and postpartum access before admission so a change of setting does not create an avoidable treatment interruption.
Common pitfall: Assuming another team will manage the transition leaves gaps in medication and follow-up. A referral name alone does not confirm that care is accessible.
57.What information makes an alcohol-withdrawal handoff useful?
A transfer handoff should explain why the current setting is insufficient and communicate the trajectory of symptoms, last alcohol exposure, prior seizures or delirium, comorbid illness, other substance use, medication already administered, and response. These details help the receiving team distinguish progression from medication effects and anticipate complications. Communicate unstable observations and immediate safety needs directly. A completed referral or copied score without clinical context does not provide enough information for reliable continuation of withdrawal treatment.
Apply it
A patient develops confusion during ambulatory withdrawal care after receiving medication. During transfer, report symptom progression, doses and timing, vital signs, prior withdrawal complications, and relevant co-exposures so the receiving team can continue assessment without guessing.
Common pitfall: Sending only the latest symptom score omits risk factors and treatment response. Confusion can have several causes, so medication history and clinical trajectory matter.
ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
Research, Ethics, & CQI5%
58.How do percentage points differ from relative improvement?
A proportion requires a defined numerator and denominator. When a completion rate changes, percentage-point change is the new percentage minus the old percentage; relative change divides that difference by the original percentage. Moving from 40% to 60% is a 20-percentage-point increase and a 50% relative increase. Report the population, time period, and denominators so the result is interpretable. An observed improvement alone does not establish that a particular service change caused it.
Apply it
A clinic's follow-up completion rises from 32 of 80 eligible patients to 48 of 80. Report 40% to 60%, an increase of 20 percentage points or 50% relative to baseline, without claiming proven causation.
Common pitfall: Calling the change a 20% relative increase confuses two measures. Changing eligibility or missing-data rules can also create an apparent improvement without better care.
AHRQ Integration Academy — Collect and Use Data for Quality Improvement
59.Why test a care improvement on a small scale first?
Small-cycle improvement links a specific aim to a limited change, measurement, review, and revision. Testing with a small group can reveal workflow barriers and unintended effects before wider implementation. Choose a process measure connected to the proposed mechanism and an outcome relevant to patients. Record what changed and when so the team can interpret the findings. A successful first cycle supports further testing; it does not automatically prove effectiveness across all patients, staff, or settings.
Apply it
An addiction clinic proposes next-day reminder calls to improve follow-up. Test the workflow with one team's patients, track calls and completed visits, review failures and workload, and adapt the process before expanding it across the clinic.
Common pitfall: Launching broadly before checking feasibility can spread a flawed workflow. A favorable short cycle also needs interpretation rather than being treated as definitive research evidence.
AHRQ Integration Academy — Collect and Use Data for Quality Improvement
60.Which measures show whether integrated addiction care is improving?
Use a small set of measures that connects care processes with patient outcomes and possible unintended burdens. Referral completion, timely follow-up, treatment engagement, and patient-reported experience answer different questions and should not be substituted for one another. Define eligibility and measurement intervals consistently. Examine whether improvement reaches different patient groups rather than relying solely on an overall average. Reviewing results with the team supports practical revisions and prevents an easily counted activity from becoming the sole definition of quality.
Apply it
A clinic increases addiction referrals but sees little change in completed visits. Track referral-to-visit completion and patient-reported access barriers, then compare results across relevant groups to identify where the integrated pathway is failing.
Common pitfall: Counting referrals alone rewards activity without demonstrating access. An improving average can conceal persistent barriers for a subgroup or increased workload elsewhere in the service.
AHRQ Integration Academy — Collect and Use Data for Quality Improvement
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Connect exposure timelines, examination findings, and assay limitations before interpreting a positive or negative drug test.
- Distinguish present withdrawal severity from future complication risk, especially with alcohol and benzodiazepines.
- Compare medication mechanisms with opioid exposure, pregnancy, renal function, hepatic risk, and pain-management needs.
- Give behavioral care meaningful attention: contingency management, skills practice, engagement, and continuing treatment are central intervention tasks.
- Practise concise education on breathing emergencies, tolerance loss, mixed substances, medication hazards, and transport safety.
- Study both blueprint axes together: opioid and alcohol problems carry the largest patient-problem weights, while the official other-disorders category extends beyond this guide.
- Measure completed care and observed change using explicit denominators, while distinguishing service improvement from causal research conclusions.
A practical preparation plan
1. Anchor the study plan to the 2026 outline
Use the official CARN-AP specifications as the full scope. Allocate study time across the five activity domains, then tag clinical topics by the overlapping patient-problem axis. Add dedicated review of other disorders beyond the examples developed here.
2. Build clinical comparison pairs
Compare detection with impairment, dependence with use disorder, withdrawal severity with complication risk, and acute stabilization with continuing treatment. State the finding that changes the decision for each pair.
3. Create a medication decision grid
For each medication, record its purpose, mechanism, decisive contraindication or caution, monitoring needs, and counseling point. Rehearse acamprosate renal limits, naltrexone opioid exposure and pain planning, pregnancy treatment, and disulfiram hazards.
4. Rehearse education aloud
Explain overdose response, recurrent sedation, tolerance loss, sedative interactions, and taper reporting in plain language. Include a concrete action and a check that the learner can describe what to do.
5. Use the questions diagnostically
Complete the 20 independent drills, then explain why each alternative is less appropriate. Classify errors as missing knowledge, a misread clinical cue, or an unjustified assumption. Revisit the relevant concept and cited clinical reference.
6. Recall and apply
Use the flashcards without looking at the answers, then change one case feature, such as renal function, recent opioid exposure, or communication ability. Explain how that change alters assessment, treatment, education, or consultation.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ANCB — Home
- ANCB — Statistics & Studies
- Certified Addictions Registered Nurse Advanced Practice — C-NET
- CARN-AP Examination Handbook — Revised January 2026
- CARN-AP Test Specifications (Blueprint) — Implemented 2026
- ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine
- ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
- ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
- NIMH — Adult Outpatient Brief Suicide Safety Assessment Guide
- ASAM — Benzodiazepine Tapering
- Joint Clinical Practice Guideline on Benzodiazepine Tapering — 2025
- NIDA Data Share — Marijuana Withdrawal Symptom Checklist
- ASAM — Opioid Use Disorder in Pregnancy
- DailyMed — VIVITROL Prescribing Information
- DailyMed — Acamprosate Calcium Prescribing Information
- CDC — Clinical Interventions to Treat Tobacco Use and Dependence Among Adults
- SAMHSA — Overdose Prevention and Response Toolkit, hosted by CDC
- DailyMed — Disulfiram Prescribing Information
- AASLD/IDSA HCV Guidance — People Who Inject Drugs
- AHRQ Integration Academy — Collect and Use Data for Quality Improvement
- CDC — Clinical Screening and Diagnosis for Hepatitis C
- CDC — Cannabis and Driving
- CDC — How to Combine Quit Smoking Medicines
- NIAAA — What Is a Standard Drink?
- ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine Consensus Document
- ASAM — Alcohol Withdrawal Management Guideline
- ASAM — Stimulant Use Disorder Guideline
- Clinical guidelines for alcohol treatment - 10. Pharmacological interventions - Guidance - GOV.UK
- asam_engagement-and-retention-of-nonabstinent-patients_final_082624.pdf
- APRN Consensus Model | NCSBN
- DailyMed - LORAZEPAM tablet
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.